These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18615172)

  • 21. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression.
    Patkar AA; Peindl K; Mago R; Mannelli P; Masand PS
    Prim Care Companion J Clin Psychiatry; 2006; 8(2):82-7. PubMed ID: 16862232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
    Sheffrin M; Driscoll HC; Lenze EJ; Mulsant BH; Pollock BG; Miller MD; Butters MA; Dew MA; Reynolds CF
    J Clin Psychiatry; 2009 Feb; 70(2):208-13. PubMed ID: 19210951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Tianeptine 25-50 mg in Elderly Patients With Recurrent Major Depressive Disorder: An 8-Week Placebo- and Escitalopram-Controlled Study.
    Emsley R; Ahokas A; Suarez A; Marinescu D; Dóci I; Lehtmets A; Milanova V; Lee MS; Didi R; Araszkiewicz A; Sulaiman AH; Blanchot FP; Crutel VS; Antoine C; Penelaud PF
    J Clin Psychiatry; 2018 Jul; 79(4):. PubMed ID: 29995359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
    Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
    J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study].
    Schmitt L; Arbus C; Tonnoir B
    Encephale; 2006; 32(2 Pt 1):270-7. PubMed ID: 16910629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study.
    Jeong JH; Bahk WM; Woo YS; Lee KU; Kim DH; Kim MD; Kim W; Yang JC; Lee KH
    Neuropsychiatr Dis Treat; 2015; 11():2557-64. PubMed ID: 26504387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dawn simulation treatment of abstinent alcoholics with winter depression.
    Avery DH; Bolte MA; Ries R
    J Clin Psychiatry; 1998 Jan; 59(1):36-42; quiz 43-4. PubMed ID: 9491067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
    J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
    Otte C; Chae WR; Nowacki J; Kaczmarczyk M; Piber D; Roepke S; Märschenz S; Lischewski S; Schmidt S; Ettrich B; Grabe HJ; Hegerl U; Hinkelmann K; Hofmann T; Janowitz D; Junghanns K; Kahl KG; Klein JP; Krueger THC; Leicht G; Prvulovic D; Reif A; Schoettle D; Strauss M; Westermair A; Friede T; Gold SM
    BMJ Open; 2020 Dec; 10(12):e040119. PubMed ID: 33262189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population.
    Jiang K; Li L; Wang X; Fang M; Shi J; Cao Q; He J; Wang J; Tan W; Hu C
    Neuropsychiatr Dis Treat; 2017; 13():515-526. PubMed ID: 28255239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled study of light therapy for antepartum depression.
    Wirz-Justice A; Bader A; Frisch U; Stieglitz RD; Alder J; Bitzer J; Hösli I; Jazbec S; Benedetti F; Terman M; Wisner KL; Riecher-Rössler A
    J Clin Psychiatry; 2011 Jul; 72(7):986-93. PubMed ID: 21535997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial.
    Kishi T; Matsuda Y; Matsunaga S; Moriwaki M; Otake Y; Akamatsu K; Okochi T; Hirano S; Funahashi T; Okuda M; Tabuse H; Fujita K; Iwata N
    Neuropsychiatr Dis Treat; 2017; 13():117-125. PubMed ID: 28123299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan.
    Asakura S; Hayano T; Hagino A; Koyama T
    Curr Med Res Opin; 2016; 32(4):749-57. PubMed ID: 26808688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.